SCHEMBL5820065

SCHEMBL5820065

O=C(Nc1ccc2[nH]c(-c3cn[nH]c3)cc2c1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
JAK2 O60674 1/20 0.59
MAOA P21397 1/20 0.59
MAOB P27338 1/20 0.59
NTRK1 P04629 1/20 0.55
ITK Q08881 3/20 0.54
MAPT P10636 3/20 0.52
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
NAMPT P43490 1/20 0.48
MMP2 P08253 2/20 0.48
MMP9 P14780 2/20 0.48
MMP8 P22894 2/20 0.48
MMP13 P45452 2/20 0.48
COMT P21964 1/20 0.48
MELK Q14680 1/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478358 0.92 NTRK1 (0.57) NPC1RAB9AJAK2MAOAMAOB
SCHEMBL5760150 0.87 ROCK2 (0.64) NPC1RAB9ANTRK1ITKMAPT
SCHEMBL14182736 0.85 MAOA (0.67) NPC1RAB9AJAK2MAOAMAOB
SCHEMBL5814937 0.83 ROCK2 (0.52) NPC1RAB9AKMT2AMEN1NAMPT
SCHEMBL5816604 0.82 RAB9A (0.56) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL5754607 0.81 NAMPT (0.71) ITKNAMPTROCK2
SCHEMBL5756127 0.81 TNIK (0.50) NTRK1NAMPTMMP13ROCK2
SCHEMBL14182733 0.81 RAB9A (0.60) NPC1RAB9AJAK2MAOAMAOB
SCHEMBL14182750 0.81 RAB9A (0.60) NPC1RAB9AJAK2MAOAMAOB
SCHEMBL6481076 0.80 PDE10A (0.51) NPC1ITKKMT2AMEN1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648884-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2006-04-26 EP disclosed
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-02-10 US disclosed
WO-2005005414-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K9, MAP3K20, MAP3K19 NPC1 3439/4885RAB9A 1147/4885JAK2 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.